SEC Form 4 · accession 0001179110-17-000723
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold Van Wart
Officer — President and CEO · Director
Period of report
Jan 4, 2017
Accepted (ET)
Jan 6, 2017 · 7:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $1.82 | Jan 4, 2017 | A | 50,000 | A | Jan 4, 2017 | Jul 24, 2026 | Common Stock | 50,000 | 100,000 | D |
Explanation of responses
- F1On July 25, 2016, the Reporting Person was granted an option to purchase 100,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met on December 30, 2016, resulting in vesting of the option as to 50,000 shares, which was reported on a prior Form 4. The second milestone was met on January 4, 2017, resulting in vesting of the option as to the remaining 50,000 shares.